Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis
Among primary liver carcinoma cases, the proportion of liver hepatocellular carcinoma (LIHC) cases is 75%–85%. Current treatments for LIHC include chemotherapy, surgical excision, and liver transplantation, which are effective for early LIHC treatment. Nevertheless, the early symptoms of liver carci...
Saved in:
| Main Authors: | Rui-Qing Zong, Hong-Yan Zhang, Xiao-Ying Li, Yi-ran Li, Ying Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Genetics Research |
| Online Access: | http://dx.doi.org/10.1155/2022/7067743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The overexpression and prognostic role of DCAF13 in hepatocellular carcinoma
by: Jianzhong Cao, et al.
Published: (2017-05-01) -
GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma
by: Ting Liu, et al.
Published: (2017-06-01) -
Comparative analysis of minor histocompatibility antigens genotyping methods
by: A. S. Vdovin, et al.
Published: (2016-08-01) -
Mechanisms of HRAS regulation of liver hepatocellular carcinoma for prognosis prediction
by: Xingbao Fang, et al.
Published: (2025-04-01) -
Minor histocompatibility antigens represented in HLA-A*02:01 and their search strategies
by: D. S. Romanyuk, et al.
Published: (2023-09-01)